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ABSTRACT 
The Effect of Recombinant Human Bone Morphogenetic Protein-2 on the 
Osseointegration of Temporary Anchorage Devices 
Eden E. Cruz 
 
Titanium has been widely used for dental implants, and in particular, roughened 
titanium surfaces have provided a means for increasing bone apposition and 
strengthening the implant-to-bone interface.  Finding a way to further increase 
osseointegration is important because there is a significant clinical benefit to patients if a 
stable anchor can be established instead of anchoring orthodontic hardware to the molars.  
In this study, the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) 
on the ability of temporary anchorage devices (TADs) to osseointegrate was investigated.  
The temporary anchorage devices (TADs) used in this study were manufactured from 
commercially pure titanium and divided into 2 types of treatments: (1) sandblasted and 
acid-etched (i.e. the control) and (2) sandblasted and acid-etched treated with Medtronic 
INFUSE® Bone Graft (recombinant human bone morphogenetic protein-2 placed on an 
absorbable collagen sponge).  The implants were placed on the cranial bones of 10 adult 
male Sprague-Dawley rats.  The rats were euthanized by carbon dioxide asphyxiation 6 
weeks following surgery for histological examination and biomechanical testing.  The 
results from visual inspection and biomechanical testing showed that the sandblasted and 
acid-etched TADs treated with rhBMP-2  promoted better osseointegration than TADs 
that were only sandblasted and acid-etched. Specifically, surface modified TADs treated 
with rhBMP-2 on bottom showed an increased surface coverage by bone and an increase 
in the adhesion strength at the TAD-to-bone interface.  
 
Key Words: temporary anchorage device, sand-blasted and acid-etched surface, rhBMP-
2, butyl cyanoacrylate, osseointegration
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1.  LITERATURE REVIEW 
 With the objective of replacing missing teeth for patients, titanium implants have 
continued to play an important role in the dental industry since the time when Dr. Per 
Ingvar Branemark discovered titanium’s biocompatibility and its ability to integrate into 
bone in the 1960’s.  Specifically, the use of titanium implants as temporary anchorage 
devices (TADs) has been a significant application in orthodontic practice for the past 5 
years.  As an alternative to using molars as anchors, which may lead to undesired teeth 
movement, these TADs offer orthodontists the ability to move teeth against fixed objects 
instead of against neighboring teeth, thus avoiding the equal and opposite reaction forces 
as described by Newton’s third law [1, 2].  
 
 Although TADs offer orthodontists unparalleled opportunities to move specific 
teeth while avoiding undesired movement of the surrounding teeth, they also present 
potential danger to patients.  Possible risks and complications that may occur if an 
insufficient amount of bone is available at the implant site include root trauma, soft-tissue 
irritation, nerve injury, sinus perforation, and damage of maxillary and mandibular 
neurovascular systems [3, 4].  Presently, TADs vary from 5 to 12 mm in length and 1.3 to 
2 mm in diameter, and thus, there is no practical way to attach a TAD and maintain 
mechanical retention without piercing the bone.  Unfortunately, this could lead to the 
risks that were previously mentioned.  Not only does a bone piercing TAD run the risks 
of possible side effects, it also introduces implant site limitations.  In order to avoid root 
trauma, a bone piercing TAD would have to be inserted between the roots.  If it were 
possible to attach a TAD as close to the surface of the bone as possible (just under the 
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periosteum) without piercing it, then serious side effects and insertion site limitations 
may be avoided.  
  
 To tackle the issue of bone height and bone piercing, Block and Hoffman 
developed the “onplant,” which is a disk-like hydroxyapatite-coated structure 
approximately 10 mm in diameter and 2mm in height.  The onplant is usually located 
subperiosteally on the posterior portion of the hard palate, and with a transpalatal arch, 
the onplant is attached to the orthodontic bands on the upper molar teeth [5].   According 
to Block and Hoffman, this mechanism has been shown to resist greater than 300 g of 
continuous orthodontic force [5].  Therefore, the onplant provides maximum anchorage 
to the molars and total anchorage for tooth movement without reciprocal movement of 
the onplant [1, 4].  Unfortunately, the surgical procedures for removing the onplant are 
intricate and involve re-exposing a large portion of soft tissue, which can be distressing 
for the patient.  Advancement in the safety of TADs and minimal discomfort for patients 
would be available if bone piercing and painful removal procedures could be prevented.  
Should surface TADs be considered?   
 
 Surface TADs seem to address the potential side effects involved with bone 
piercing, but like bone piercing TADs, surface TADs present limitations that are worth 
considering.  Unlike bone piercing TADs that are long and wide and can provide 
mechanical retention, surface TADs lack mechanical retention.  Without this mechanical 
retention, the ability to achieve absolute anchorage is minimal.  If it were possible to 
strengthen the interface between the TAD and bone, then orthodontic anchorage may be 
 3 
established.  During the 1960’s, Dr. Per Ingvar Branemark introduced the phenomenon of 
“osseointegration,” which meant the direct structural and functional connection between 
living bone and the surface of a load-bearing implant [1, 6].  Through experimentation, 
Branemark found that titanium itself integrates into bone.  Titanium microscope heads 
placed into the thighbone of a rabbit could not be taken out during the removal process 
because the titanium oxide at the surface of the microscope heads had permanently fused 
with the bone.  If it were possible to use titanium as the implant material for TADs, then 
mechanical retention and a stable anchor could be obtained. 
 
 Titanium has been used for artificial hip joints for many years, and unlike other 
alloys, titanium has been shown to be biocompatible with the human body.  In addition to 
its biocompatibility, titanium is lightweight, strong, corrosion and fracture resistant, has 
low thermal conductivity, and can be machined and formed easily [7, 8].  Furthermore, its 
titanium oxide layer allows the direct contact between a titanium implant surface and 
bone (i.e. osseointegration).  While stainless steel has also been used in orthodontics 
because of its high strength, it cannot be shaped easily like titanium because of its high 
linear coefficient of thermal expansion.  In addition, stainless steel’s high nickel content 
makes stainless steel less desirable in terms of biocompatibility because nickel is not 
biocompatible.  Therefore, titanium, with its excellent biocompatibility, is the more 
desirable choice for implant material.   
 
 Taking it a step further, not only is the implant material important, but the implant 
surface itself is also a critical factor in promoting osseointegration [9, 10, 11, 12]. For 
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example, titanium surfaces with microscale roughness have been shown to enhance 
osseous apposition by increasing the total surface area available for bone formation. In 
particular, a combination of sandblasting and acid-etching techniques has been effective 
in producing these microrough titanium surfaces [10, 11]. Implants with sandblasted and 
acid-etched surfaces have increased osteoblastic attachment and differentiation, which in 
turn, have strengthened bone implant contact and enhanced removal torque values in 
biomechanical testing. 
 
 Currently, sandblasted and acid-etched surfaces are considered a high standard of 
treatment for titanium implants, but is there a way to improve surface modifications to 
further increase osseointegration and implant stability? If additional modifications can be 
made to the TAD surface, the TAD can act as a stable anchor while eliminating the need 
to puncture the bone.  By finding a way to further enhance osseointegration, the surface 
modification necessary for optimal bone apposition and optimal quality of the bone-TAD 
interface can be achieved. 
 
The use of bone morphogenetic protein (BMP) can be a means of achieving the 
desired surface modifications.  BMPs are a group of growth factors, which for decades 
now, have been studied and investigated because of their ability to induce bone and 
cartilage formation [13, 14, 15, 16]. BMPs have demonstrated the ability to heal bone, 
which in turn, has eliminated the need for bone harvesting from other parts of the body. 
Since its discovery in the 1960s by Urist, so far, approximately 20 BMPs have been 
identified and characterized. Of these twenty BMPs, BMPs 2-9 belong to the 
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transforming growth factor-β (TGF–β) superfamily. Within this TGF–β superfamily, two 
members in particular, BMP-2 and BMP-7, have become the subject of extensive 
research.  Exhibiting great osteogenic capacity, BMP-2 and BMP-7 have the ability to 
radically induce osteoblast differentiation in a variety of cell types and their significance 
in bone development is supported in various experimental studies [15, 17]. Furthermore, 
BMP-2 and BMP-7 have shown great potential in therapeutic applications, specifically in 
the treatment of bone-related conditions and defects.  
 
From the time BMPs were first discovered, their importance in healing bone and 
stimulating bone growth within the body has been undeniable. When BMPs were 
discovered more than 40 years ago, they were naturally occurring within the bone matrix 
itself. However, for the first time in 1988, these naturally occurring proteins were isolated 
and genetically reproduced to form recombinant human bone morphogenetic protein, or 
rhBMP. Like the naturally occurring protein, the recombinant form, according to several 
preclinical studies, has demonstrated the ability to induce new bone growth [16, 18, 19, 
20]. Specifically, rhBMP-2 has been studied more than any other BMP and has been 
approved by the Food and Drug Administration (FDA) for use in tibial, oral, and spinal 
surgical procedures. Furthermore, studies have shown that when rhBMP-2 is used with a 
carrier, for example a collagen sponge, it has the ability to improve spinal fusion, 
increase periodontal new bone formation, and encourage fracture repair. In addition, 
rhBMP-2 has been used to regenerate defects of the mandible and skull, and help in the 
treatment of non-union, delayed union, and other skeletal conditions [13, 15, 18, 19]. 
Clearly, rhBMP-2 has been effective in several types of applications and therefore is 
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chosen for this current study. In particular, Medtronic INFUSE® Bone Graft, which uses 
an absorbable collage sponge (ACS) as a carrier for the rhBMP-2, is used. 
 
Medtronic INFUSE® Bone Graft has been used in various applications and has 
the capability of facilitating bone growth in different parts of the body. In tibial fractures, 
it has aided in the healing of broken bones, and in the spine, it has helped minimize back 
pain and maximize spine stability by allowing the vertebrae to fuse. Moreover, Medtronic 
INFUSE® Bone Graft has helped in localized alveolar ridge augmentation and sinus 
augmentation, types of maxillofacial and oral grafting procedures.  
 
Recombinant human bone morphogenetic protein-2 has great potential in 
facilitating new bone growth and promoting enhanced osseointegration, but its ability to 
do so relies greatly on implant stabilization. The ability of a TAD to osseointegrate is 
compromised when implant stabilization is not present because the potential for 
microfractures at the bone-TAD interface increases. Osseointegration does not occur 
instantly, and thus, during this waiting period, it is critical to find a way to stabilize the 
TAD. This is very important because a “loose” TAD could influence the effectiveness of 
the rhBMP-2.  
 
In orthodontic practices, the screw TAD has been one solution to achieving 
implant stabilization [1, 4, 5]. The screw TAD has been widely used because of its ability 
to generate static equilibrium. In other words, the sum of all the forces and the sum of all 
the moments about a point is zero [1]. Screw TADs, which are threaded into bone, create 
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mechanical resistance so that implant stability can occur. The problem with screw TADs, 
however, is that it involves puncturing of the bone. This defeats the purpose of the study 
which is to eliminate puncture of the bone while promoting enhanced osseointegration. 
Therefore, another method aside from screw TADs must be considered to achieve desired 
implant stability. 
 
The use of cyanoacrylate, or “tissue glue,” can be a means of stabilizing the TAD 
without having to puncture the bone. Cyanoacrylates have been used in a variety of 
applications ranging from the manufacture of electronics, shoes, and sports equipment, to 
areas of dentistry and surgery [21].  As a whole, cyanoacrylates have been very useful in 
general and medical applications. Cyanoacrylate tissue adhesives have been shown to 
have similar results to suturing and to be a considerably faster method of skin edge 
apposition in small facial lacerations [22].  In fact, it has been used to seal wounds and 
stop bleeding since the time of the Vietnam War. More specifically, there are several 
types of cyanoacrylates, which include methyl, ethyl, butyl, and octyl cyanoacrylate. In 
most cases, the type of cyanoacrylate that is used depends on the specific application. 
Methyl cyanoacrylate, for example, works well for metal bonding applications, whereas 
ethyl cyanoacrylate works well for bonding plastics, metals, and rubber. Butyl 
cyanoacrylate is notable for bonding tissues and can be used as an alternative to suturing 
[22, 23]. Finally, octyl cyanoacrylate is useful for surface wound healing. In general, 
cyanoacrylates are useful because they have fast curing times. Implant stability is 
essential for osseointegration to occur.  Cyanoacrylates provide a way to avoid damage to 
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the bone and increase the likelihood of osseointegration by creating a stable temporary 
anchorage device. 
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2.  RESEARCH & SPECIFIC AIMS 
2.1  Objective 
Titanium has been widely used for dental implants, and in particular, roughened 
titanium surfaces (i.e. sandblasted and acid-etched) have provided a means for 
accelerating osseointegration and strengthening the bone-implant interface. The goal of 
this study is to determine the effect of recombinant human bone morphogenetic protein-2 
(rhBMP-2), or more specifically, Medtronic INFUSE® Bone Graft, on the ability of 
temporary anchorage devices (TADs) to osseointegrate.  In particular, this study will 
determine the influence of rhBMP-2 in addition to a sandblasted and acid-etched surface 
on implant anchorage and increased bone formation.  Finding a way to increase 
osseointegration is important because there is a significant clinical benefit to patients if a 
stable anchor can be established instead of anchoring orthodontic hardware to the molars.  
Moreover, increasing osseointegration of surface TADs would ideally minimize 
interfacial movement, prevent slip, and increase long-term implant stability without 
piercing the bone. 
 
2.2  Specific Aim  
To investigate the influence of recombinant human bone morphogenetic protein-2 
(rhBMP-2) on the osseointegration of temporary anchorage devices (TADs). This will 
involve qualitative examination of the TAD surface covered by bone through the means 
of visual inspection and photographs.  The surface coverage of a sandblasted/acid-
etched/rhBMP-2 treated TAD will be compared to the surface coverage of a control 
specimen (a sandblasted and acid-etched titanium TAD). In addition, mechanical testing 
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will be done to determine if the rhBMP-2 treatment on the TAD produces any significant 
changes in the bond strength between the bone and TAD.  
 
2.3  Hypothesis 
Sandblasted and acid-etched temporary anchorage devices (TADs) treated with 
recombinant human bone morphogenetic protein-2 (rhBMP-2) will promote better 
osseointegration than TADs that are only sandblasted and acid-etched. Specifically, 
surface modified TADs treated with rhBMP-2 on bottom will show an increased surface 
coverage by bone and an increase in the adhesion strength at the bone-to-TAD interface.  
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3.  MATERIALS & METHODS 
3.1   Rationale for Species & Numbers 
Ten adult male Sprague-Dawley rats (4 controls and 6 treated with the absorbable 
collagen sponge/rhBMP-2 mixture) with average weight of 359 ± 108 g were used for 
this study and handled in accordance with an IACUC approved protocol and with the 
National Institutes of Health (NIH) guidelines for the care and use of laboratory animals 
(NIH publication 85-23, Rev. 1985).  Specifically, Simonsen albino adult male rats were 
chosen for this study.  In addition, the number of rats was calculated using the 1-Sample t 
test to ensure that a sufficient amount of data would be produced while limiting the 
number of rats used.    The Sprague-Dawley rat was selected as the appropriate species of 
choice due to its genetic similarity to humans and its ability to serve as a general model 
for the study of human health and disease.  Sprague-Dawley rats are widely used for 
experimental purposes, and in particular, their calmness and ease of handling make them 
the choice of species for this study.  Studies similar to this current study have shown 
sound scientific results with the use of Sprague-Dawley rats.    
 
3.2   Surgical Procedures 
3.2.1   Introduction 
The details of each rat surgery, such as time of injection, initiation of surgery, 
monitoring of rat vitals, and completion time of surgery are recorded in a lab notebook. 
See Appendix A for a copy of this raw data.  The surgical procedures are based on the 
results of preliminary experiments (Appendix B).  To ensure that each surgery was 
performed smoothly for each animal, the surgery checklist in Appendix C was used. 
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3.2.2   Implant Preparation 
The temporary anchorage devices (TADs) used in this study were manufactured 
from commercially pure titanium and divided into 2 types of treatments: Type 1 was 
sandblasted (with grit) and acid-etched (combination of anorganic acids, HCl/H2SO4 acid 
bath), and Type 2 was treated with Medtronic INFUSE® Bone Graft (recombinant 
human bone morphogenetic protein-2 placed on an absorbable collagen sponge) in 
addition to a sandblasted and acid-etched treatment.  Type 1 treated surfaces served as the 
control TADs for this study because previous studies have shown that the combination of 
sandblasting and acid-etching is a high standard of treatment for titanium that creates a 
modified surface topography and allows for enhanced bone apposition and bone implant 
contact.  An absorbable collagen sponge soaked in saline was used for the control TAD in 
order to reduce the variability of the results and focus solely on the effect of the rhBMP-2 
on the osseointegration of the TAD. Type 2 treated surfaces were also sandblasted and 
acid-etched, but had an additional treatment of Medtronic INFUSE® Bone Graft on 
bottom in order to determine if rhBMP-2 improves on the already working technology 
(sandblasted and acid-etched treatment).   
 
For a Type 1 TAD, a 1 cm x 1 cm absorbable collagen sponge (ACS) was treated 
with 0.09 cc of saline using a sterile syringe and sterile tray.  Refer to Figure 3.1.  
Similarly, for a Type 2 treated TAD, a 1 cm x 1 cm absorbable collagen sponge was 
treated with 0.09 cc of reconstituted rhBMP-2 using a sterile syringe and sterile tray.  The 
absorbable collagen sponge with either saline or rhBMP-2 was set for at least 15 minutes 
before use.   
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Figure 3.1   1 cm x 1 cm ACS treated with 0.09 cc of saline 
 
3.2.3   Pre-Operative  
The dosages administered to the Sprague-Dawley rats for general anesthesia and 
pain medication were based on the weight of the animal.  A mixture of Ketamine and 
Xylazine (44 mg/kg body weight of Ketamine, 10 mg/kg body weight of Xylazine) was 
used for inducting general anesthesia.  This provided approximately 30 minutes of 
effective anesthesia.  In addition, a dose of Buprenorphine was administered 
subcutaneously (0.01 – 0.05 mg/kg body weight) between the shoulder blades for pain 
mitigation.  Refer to Appendix D for the table of weights and the respective dosages for 
Ketamine, Xylazine, and Buprenorphine.  The dosages were recorded in a lab notebook 
which is under lock and key at the California Polytechnic State University, San Luis 
Obispo surgical suite. The Ketamine/Xylazine and Buprenorphine mixture worked well 
because emergence from anesthesia was smoother and had a high factor of safety.  Under 
anesthesia, the rat did not respond to various audible and tactic stimuli, but maintained 
normal breathing and heart rate.  Once the rat was in Stage 3 and the anesthesia had taken 
effect, the rat was ready to undergo prepping procedures.   
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For surgery, the rat was prepped by shaving the surgical site (rat’s head), applying 
depilatory cream to remove excess hair, and disinfecting the area with Betadine solution 
using sterile cotton swabs applied in a circular motion.  This process was preformed 3 
times (with 3 different cotton swabs), and the antiseptic was in contact with the skin for a 
minimum of 3 minutes before incision.  Prior to surgery, a sterile surgical drape was put 
over the animal to ensure that aseptic standards were met. 
 
3.2.4   Operative  
Using the “tips-only” technique, an incision was made along the midline of the 
head from the eyes to the ears. Once the incision was made, the periosteum was carefully 
held back to expose the bony complex on the surface of the cranium.  Sterile forceps 
were used to pick up a temporary anchorage device and place it on the surface of the 
cranial bone (either on the frontal or parietal bone) in order to contour it to fit the shape 
of the animal’s skull.  A sterile instrument was used to place the collagen sponge (wet 
with saline or rhBMP-2) on the rat skull before placing the TAD on top of it and 
stabilizing the TAD with butyl cyanoacrylate.  The butyl cyanoacrylate took 
approximately 2 minutes to set.  While surgery was in progress, the animal’s vital signs 
were continually monitored.  Once the implant was in place, the incision was closed 
using butyl cyanoacrylate. 
 
3.2.5  Post-Operative  
After surgery and the removal of the surgical drape, the rat was moved to a warm 
area (recovery bin) where it was monitored during recovery.  A heating pad was used to 
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return the animal’s body temperature back to normal.  Upon full recovery from the 
anesthesia, the rat was returned to its routine housing; each rat was caged separately.  
Buprenorphine (0.01 -0.05 mg/kg) was administered 3 times a day for 2 days as 
necessary for pain management.  In the event of an infection, the wound site was cleaned 
2 times/day with Betadine solution.  The rats were visually inspected daily post-op for 
infection, and a surgical record (procedure, date, anesthesia dose, route of administration) 
was maintained.  The rats were euthanized by carbon dioxide asphyxiation 6 weeks after 
surgery for histological evaluation and biomechanical testing. 
 
3.3   Histological Evaluation 
After the rats were euthanized by carbon dioxide asphyxiation, a qualitative 
analysis was performed.  Qualitative analysis included examining surface topography and 
the amount of the TAD surface covered by bone through photographs and visual 
inspection.  A comparison of surface topography and TAD coverage was made between 
the rhBMP-2 treated TAD and the control specimen (sandblasted and acid-etched TAD).  
 
3.4   Biomechanical Testing 
3.4.1   Proof of Experimental Concept 
 As proof of experimental concept, the shear strength of the orthodontic implant 
was mechanically tested using a polyurethane block. The test involved imbedding the 
device onto a polyurethane 20 lb foam block and attaching it to a micromechanical 
testing system (In Spec, Instron Corporation, Camden, MA) with a 50 N load cell (see 
Figure 3.2). Five replicate tests were conducted with an average shear load of 8.9 ± 1.5 
N.   
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Figure 3.2   Proof of experimental concept 
 
 
3.4.2   Test Setup for Biomechanical Testing 
Biomechanical testing was performed using a micromechanical testing system (In 
Spec, Instron Corporation, Camden, MA).  The rat head was secured in a chuck in 
preparation for biomechanical testing.  A string was attached from the protruding part of 
the TAD to the Instron machine.  Refer to figures 3.3 and 3.4.  To test initial stability of 
the temporary anchorage device, load was applied to the upper part of each TAD in the 
shear direction (right angle to an implant) with a force at constant speed until the 
surrounding bone was destroyed.   
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Figure 3.3   Biomechanical test setup  
 
 
Figure 3.4   Applying load in the shear direction with a force at constant speed 
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4.  RESULTS 
4.1   TAD Bone Coverage 
Table 4.1   TAD bone coverage 
Rat # Control or rhBMP-2 treated Bone Coverage 
Rat 4 Control, sponge on bottom 
Bone coverage observed; however, data 
discarded as TAD was left in rat for over 6 
weeks 
Rat 8 Control, sponge on bottom 10% bone coverage 
Rat 12 Sponge on bottom w/ rhBMP-2 35% bone coverage 
Rat 13 Control, sponge on bottom 20% bone coverage 
Rat 14 Sponge on bottom w/ rhBMP-2 40% bone coverage 
Rat 15 Sponge on bottom w/ rhBMP-2 80% bone coverage 
Rat 16 Control, sponge on bottom 15% bone coverage 
Rat 17 Sponge on bottom w/ rhBMP-2 45% bone coverage 
Rat 18 Sponge on bottom w/ rhBMP-2 95% bone coverage 
Rat 20 Control, sponge on bottom No bone coverage observed – TAD stuck to 
soft tissue 
Rat 25 Sponge on bottom w/ rhBMP-2 30% bone coverage 
 
The raw data (photographs of TAD bone coverage) for each rat is found in Appendix E.  
The TAD bone coverage summary, including mean and standard deviation, is represented 
in Figure 4.1 below. 
TAD Bone Coverage Summary
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Figure 4.1   TAD bone coverage summary 
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4.2   Biomechanical Testing: Failure Load 
Table 4.2   Biomechanical testing: measuring failure load 
Rat # Control or rhBMP-2 treated? Failure Load 
Rat 4 Control, sponge on bottom 8.38 N - Data discarded as TAD was left in 
rat for over 6 weeks 
Rat 8 Control, sponge on bottom 2.56 N 
Rat 12 Sponge on bottom w/ rhBMP-2 5.13 N 
Rat 13 Control, sponge on bottom 4.53 N 
Rat 14 Sponge on bottom w/ rhBMP-2 15.12 N 
Rat 15 Sponge on bottom w/ rhBMP-2 32.72 N 
Rat 16 Control, sponge on bottom 2.84 N 
Rat 17 Sponge on bottom w/ rhBMP-2 7.03 N 
Rat 18 Sponge on bottom w/ rhBMP-2 84.47 N 
Rat 20 Control, sponge on bottom 0 N – TAD was loose and stuck to soft tissue 
Rat 25 Sponge on bottom w/ rhBMP-2 11.29 N 
 
The failure load graph (i.e. force-displacement curve) for each rat is found in Appendix 
F.  The failure load summary, including mean and standard deviation, is represented in 
Figure 4.2 below. 
Biomechanical Testing: Failure Load Summary 
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Figure 4.2   Biomechanical testing: failure load summary 
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5.  DISCUSSION 
 
5.1   TAD Bone Coverage  
Bone coverage was present on all rhBMP-2 treated TADs and all but one of the 
control TADs.  This observation was made through visual inspection and photographs 
taken prior to biomechanical testing. For the control TAD in Rat #20, no bone coverage 
was observed because the TAD had lost contact with the bone sometime during the 6 
week implantation.  It is most likely that the TAD had become loose early on before any 
osseointegration could be achieved. The TAD may have gotten loose because an 
insufficient amount of butyl cyanoacrylate was used to secure the TAD to the bone.  
 
In addition, through visual inspection and photographs, it was discovered that the 
TADs that had been treated with rhBMP-2 showed significantly more bone coverage than 
the control TADs.  The rhBMP-2 treated TADs and the control TADs both have a 
sandblasted and acid-etched surface, which alone has been shown to facilitate bone 
growth.  However, with the additional rhBMP-2 surface treatment, the TADs showed 
even better osseointegration and percent TAD surface covered by bone.  Specifically, the 
average % bone coverage of the control TADs was 11.25 ± 8.54%, while the average % 
bone coverage of the rhBMP-2 treated TADs was 54.17 ± 26.72%.  The % TAD bone 
coverage summaries (assuming 95% confidence) for Treatment 1 (control) and Treatment 
2 (rhBMP-2) are represented in figures 5.1 and 5.2 below.  These summaries show that 
the 95% confidence intervals for the mean are (-2.338, 24.838) and (26.122, 82.212) for 
the control TADs and rhBMP-2 treated TADs respectively.  The lower limit of 26.12% 
bone coverage for the rhBMP-2 treated TAD is greater than the upper limit of 24.84% 
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bone coverage for the control TAD.  Therefore, for 95% of the time, an rhBMP-2 treated 
TAD will show greater % surface coverage by bone than a control TAD.   
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Figure 5.1   TAD bone coverage summary for treatment 1 (control) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
100806040
Median
Mean
90807060504030
1st Q uartile 33.750
Median 42.500
3rd Q uartile 83.750
Maximum 95.000
26.122 82.212
31.786 89.643
16.681 65.543
A -Squared 0.50
P-V alue 0.119
Mean 54.167
StDev 26.724
V ariance 714.167
Skewness 0.95187
Kurtosis -1.10487
N 6
Minimum 30.000
A nderson-Darling Normality  Test
95% C onfidence Interv al for Mean
95% C onfidence Interv al for Median
95% C onfidence Interv al for StDev
95% Confidence Intervals
Summary for Treatment 2 (rhBMP-2)
 
Figure 5.2   TAD bone coverage summary for treatment 2 (rhBMP-2) 
 
5.2   Strength at TAD/Bone Interface 
The failure loads for the TADs treated with rhBMP-2 were significantly higher 
than the failure loads for the control TADs. On average, the force needed to pull a control 
TAD off the bone was 2.48 ± 1.87 N, while the average force needed to pull an rhBMP-2 
treated TAD off the bone was 25.96 ± 30.31 N.  The failure load summaries (assuming 
95% confidence) for Treatment 1 (control) and Treatment 2 (rhBMP-2) are represented in 
figures 5.3 and 5.4 below. 
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Figure 5.3   Failure load summary for treatment 1 (control) 
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Figure 5.4   Failure load summary for treatment 2 (rhBMP-2) 
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For the control TAD, the failure load of 0 N (data for Rat #20) was included. This 
TAD had a failure load of 0 N because it had migrated or become loose sometime during 
its 6 week implantation on the rat’s skull.  When the rat’s skull was re-exposed to 
investigate the results, it was found that the TAD was stuck to the soft tissue and no 
longer had any contact with the bone. Thus, TAD stability was lost, preventing 
osseointegration.  The most likely reason for the TAD coming loose is that not enough 
butyl cyanoacrylate was used to ensure TAD stability.   
 
Taking a closer look at the measured failure load values for the rhBMP-2 treated 
TADs, the values ranged anywhere from 5.13 N (minimum) to 84.47 N (maximum), 
hence the large standard deviation and variance as indicated in Figure 5.4 (failure load 
summary for Treatment 2 (rhBMP-2)).  It is suspected that the variability in these values 
is due to the stability of the TAD.  The more stable the TAD, the greater the chance for 
enhanced osseointegration.  How stable the TAD is prior to osseointegration is dependent 
on how well the butyl cyanoacrylate can “glue” the TAD to the bone.  The absorbable 
collagen sponge, which acted as the carrier for the rhBMP-2, was placed between the 
TAD and the bone and made it even more challenging to stabilize the TAD with the 
cyanoacrylate.  In addition, the contour and shape of each rat skull varied, and therefore, 
some TADs fit closer than others.  All the factors mentioned above had an effect on how 
much bone formed and how strong the TAD-to-bone interface was.  The failure loads 
varied between each TAD/rat even though the same procedure, test methods, and 
materials were used.  Despite the large variance in the failure load values for the rhBMP-
2 treated TADs, the minimum measured failure load value for the rhBMP-2 treated TAD 
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of 5.13 N was still greater than the maximum failure load measured for the control TAD 
of 4.53 N.   
 
  According to Figure 5.3, the 95% confidence interval for the mean failure load 
for a control TAD is -0.4928 N to 5.4578 N.  In addition, according to Figure 5.4, the 
95% confidence interval for the mean failure load for an rhBMP-2 treated TAD is -5.850 
N to 57.770 N.  The confidence interval for the rhBMP-2 treated TAD shows that it is 
possible that no osseointegration will occur for an rhBMP-2 treated TAD because the 
failure load value could be 0 N (which lies between the lower and upper limits of the 
confidence interval).  In addition, it is possible that the failure load of an rhBMP-2 treated 
TAD could be equal or similar to the failure load of a sandblasted and acid-etched 
(control) TAD since their confidence intervals overlap at some point.  Therefore, a 
control TAD may osseointegrate just as well as an rhBMP-2 treated TAD.  However, the 
upper limit (with 95% confidence) for the rhBMP-2 treated TAD (57.770 N) is 
approximately 10 times greater than the upper limit (with 95% confidence) for the control 
TAD (5.4578 N).  Thus, for 95% of the time, the failure load of the control TAD (even at 
its maximum) is not likely to reach or exceed the potential adhesion strength of an 
rhBMP-2 treated TAD.  In this study, only one rhBMP-2 treated TAD, measuring 5.13 N 
for its failure load, fell below the upper limit (5.4578 N) of the control TAD confidence 
interval.  Five of the six rhBMP-2 treated TADs achieved failure loads greater than the 
upper limit of the control TAD confidence interval.  Therefore, on average, the rhBMP-2 
treated TADs showed an increase in the adhesion strength at the TAD-to-bone interface 
when compared to the control (sandblasted and acid-etched) TADs. 
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6.  CONCLUSIONS 
The results from visual inspection and biomechanical testing show that, on average, 
the sandblasted and acid-etched temporary anchorage devices (TADs) treated with 
recombinant human bone morphogenetic protein-2 (rhBMP-2) promote better 
osseointegration than TADs that are only sandblasted and acid-etched. Specifically, 
surface modified TADs treated with rhBMP-2 showed an increased % surface coverage 
by bone and an increase in the adhesion strength at the TAD-to-bone interface.  
 
Using TADs treated with rhBMP-2 promotes enhanced osseointegration which would 
help increase long-term TAD stability without piercing the bone.  By avoiding direct 
insertion into the bone, this reduces the likelihood of developing bone infections.  
Moreover, before osseointegration can be achieved, it is critical that TAD stability be 
established. As evident in the results, this stability can be achieved using butyl 
cyanoacrylate.  By increasing osseointegration, TADs treated with rhBMP-2 can provide 
a significant clinical benefit to patients by establishing a stable anchor and thus 
eliminating the need to anchor orthodontic hardware to the molars.   
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Appendix A 
Data from Lab Notebook: Rat#, Surgery Details 
 
Table A.1   Surgical details from lab notebook 
Rat # Date Sponge Type Time Action 
4 9/1/2008 Control, sponge 
on bottom 
11:00am IP injection of 0.21cc Ketamine 
and 0.24cc Xylazine 
Subcutaneous injection of 0.047cc 
Buprenorphine and 15cc saline 
   11:20am Apply 0.09cc saline on collagen 
sponge 
   11:21am Start incision 
   11:55am Surgery completed 
   1:32pm Rat movement; began recovery 
from anesthesia 
 9/2/2008  9:00am Subcutaneous injection of 0.047cc 
Buprenorphine  
 10/12/2008  11:00pm Euthanized by CO2 asphyxiation 
     
8 10/4/2008 Control, sponge 
on bottom 
6:40am IP injection of 0.20cc Ketamine 
and 0.23cc Xylazine 
Subcutaneous injection of 0.046cc 
Buprenorphine and 15cc saline 
   6:50am Apply 0.09cc saline on collagen 
sponge 
   7:00am Start incision 
   7:20am Surgery completed 
   7:47am Rat movement; began recovery 
from anesthesia 
 10/5/2008  8:00am Subcutaneous injection of 0.046cc 
Buprenorphine  
 11/15/2008  5:45pm Euthanized by CO2 asphyxiation 
     
12 10/4/2008 Sponge on 
bottom with 
rhBMP-2 
3:02pm Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
   3:08pm IP injection of 0.19cc Ketamine 
and 0.22cc Xylazine 
Subcutaneous injection of 0.044cc 
Buprenorphine and 15cc saline 
   3:40pm Additional IP injection of 0.15cc 
Ketamine and 0.15cc Xylazine 
   4:15pm Start incision 
   4:41pm Surgery completed 
   6:00pm Rat movement; began recovery 
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Rat # Date Sponge Type Time Action 
from anesthesia 
 10/5/2008  8:05am Subcutaneous injection of 0.044cc 
Buprenorphine  
 11/15/2008  5:55pm Euthanized by CO2 asphyxiation 
     
13 10/4/2008 Control, sponge 
on bottom 
3:15pm IP injection of 0.20cc Ketamine 
and 0.23cc Xylazine 
Subcutaneous injection of 0.046cc 
Buprenorphine and 15cc saline 
   3:19pm Apply 0.09cc saline on collagen 
sponge 
   3:21pm Additional IP injection of 0.15cc 
Ketamine and 0.15cc Xylazine 
   3:40pm Start incision 
   4:09pm Surgery completed 
   5:20pm Rat movement; began recovery 
from anesthesia 
 10/5/2008  8:08am Subcutaneous injection of 0.046cc 
Buprenorphine  
 11/15/2008  5:55pm Euthanized by CO2 asphyxiation 
     
14 10/4/2008 Sponge on 
bottom with 
rhBMP-2 
4:19pm IP injection of 0.18cc Ketamine 
and 0.20cc Xylazine 
Subcutaneous injection of 0.044cc 
Buprenorphine and 15cc saline 
   4:29pm Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
   4:30pm Additional IP injection of 0.15cc 
Ketamine and 0.15cc Xylazine 
   4:56pm Additional IP injection of 0.10cc 
Ketamine and 0.10cc Xylazine 
   4:59pm Start incision 
   5:15pm Surgery completed 
   6:30pm Rat movement; began recovery 
from anesthesia 
 10/5/2008  8:12am Subcutaneous injection of 0.044cc 
Buprenorphine  
 11/15/2008  6:00pm Euthanized by CO2 asphyxiation 
     
15 10/4/2008 Sponge on 
bottom with 
rhBMP-2 
4:52pm IP injection of 0.15cc Ketamine 
and 0.18cc Xylazine 
Subcutaneous injection of 0.035cc 
Buprenorphine and 15cc saline 
   5:00pm Apply 0.09cc reconstituted BMP-2 
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Rat # Date Sponge Type Time Action 
on collagen sponge 
   5:20pm Start incision 
   6:00pm Surgery completed 
   7:45pm Rat movement; began recovery 
from anesthesia 
 10/5/2008  8:16am Subcutaneous injection of 0.035cc 
Buprenorphine  
 11/15/2008  6:00pm Euthanized by CO2 asphyxiation 
     
16 10/4/2008 Control, sponge 
on bottom 
8:48pm IP injection of 0.16cc Ketamine 
and 0.18cc Xylazine 
Subcutaneous injection of 
0.0368cc Buprenorphine and 15cc 
saline 
   8:55pm Apply 0.09cc saline on collagen 
sponge 
   9:00pm Start incision 
   9:17pm Surgery completed 
   10:40pm Rat movement; began recovery 
from anesthesia 
 10/5/2008  8:20am Subcutaneous injection of 0.035cc 
Buprenorphine  
 11/15/2008  6:07pm Euthanized by CO2 asphyxiation 
     
17 10/4/2008 Sponge on 
bottom with 
rhBMP-2 
9:05pm Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
   9:18pm IP injection of 0.17cc Ketamine 
and 0.19cc Xylazine 
Subcutaneous injection of 
0.0379cc Buprenorphine and 15cc 
saline 
   9:25pm Start incision 
   9:43pm Surgery completed 
   11:00pm Rat movement; began recovery 
from anesthesia 
 10/5/2008  8:23am Subcutaneous injection of 
0.0379cc Buprenorphine  
 11/15/2008  6:07pm Euthanized by CO2 asphyxiation 
     
18 10/4/2008 Sponge on 
bottom with 
rhBMP-2 
9:05pm Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
   9:30pm IP injection of 0.20cc Ketamine 
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Rat # Date Sponge Type Time Action 
and 0.23cc Xylazine 
Subcutaneous injection of 
0.0454cc Buprenorphine and 15cc 
saline 
   9:48pm Start incision 
   10:02pm Surgery completed 
   11:30pm Rat movement; began recovery 
from anesthesia 
 10/5/2008  8:25am Subcutaneous injection of 
0.0454cc Buprenorphine  
 11/15/2008  6:15pm Euthanized by CO2 asphyxiation 
     
20 10/5/2008 Control, sponge 
on bottom 
8:55am Apply 0.09cc saline on collagen 
sponge 
   8:56am IP injection of 0.17cc Ketamine 
and 0.19cc Xylazine 
Subcutaneous injection of 
0.0377cc Buprenorphine and 15cc 
saline 
   9:06am Start incision 
   9:22am Surgery completed 
   10:55am Rat movement; began recovery 
from anesthesia 
 10/6/2008  8:00am Subcutaneous injection of 
0.0377cc Buprenorphine  
 11/15/2008  6:30pm Euthanized by CO2 asphyxiation 
     
25 2/7/2009 Sponge on 
bottom with 
rhBMP-2 
4:05pm IP injection of 0.20cc Ketamine 
and 0.20cc Xylazine 
Subcutaneous injection of 
0.0454cc Buprenorphine and 15cc 
saline 
   4:10pm Apply 0.09cc saline on collagen 
sponge 
   4:15pm Start incision 
   4:10pm Surgery completed 
   5:00pm Rat movement; began recovery 
from anesthesia 
 2/8/2009  8:25am Subcutaneous injection of 
0.0454cc Buprenorphine  
 3/21/2009  2:30pm Euthanized by CO2 asphyxiation 
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Appendix B 
Preliminary Experiments  
B.1   Evaluating Butyl Cyanoacrylate 
 In the presence of moisture, cyanoacrylates rapidly polymerize and set quickly. A 
quick and easy way to test whether a certain type of cyanoacrylate will adhere to tissue 
with degrees of moisture is to apply the cyanoacrylate to designated sections of the 
implant and see if it adheres to cow bone or fresh meat from the grocery store.  The tissue 
found in cow bone is similar to the tissue found in rats, and therefore using the cow bone 
allows for quick and effective testing without having to perform surgery on the rat for 
this preliminary step.  
 
 In addition, saliva added to the site of the implant accounts for the presence of 
blood during the actual surgery. This aids in determining whether the saliva, with 
chemical and physical components somewhat similar to blood, will have any effect on the 
implant’s ability to adhere. From this experiment, the curing time and whether the 
cyanoacrylate is an effective adhesive can be determined. Moreover, the effect of UV 
light (which has been known to reduce curing time) will also be evaluated. Finding a way 
to reduce the curing time is desired to ensure implant stability and to minimize the 
amount of blood flow and other fluids into the implant site.  
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 An experiment using Vetbond butyl cyanoacrylate was performed.  The results 
from the experiment can be found in the following table:  
 
Table B.1   Evaluating butyl cyanoacrylate 
All trials used saliva to account for the presence of blood 
 
Curing Time 
Without UV 
Light 
(Trial 1) 
Curing Time 
Without UV 
Light 
(Trial 2) 
Curing Time 
With UV 
Light 
(Trial 1) 
Curing Time 
With UV 
Light 
(Trial 2) 
Cow 
Bone 
 
2 minutes 2 minutes 1 minute, 50 
seconds 
1 minute, 55 
seconds 
New 
York 
Steak 
Bone In 
(Shaved 
Bone) 
2 minutes 2 minutes 1 minute, 50 
seconds 2 minutes 
 
 
The curing time was determined based on the following graphs: 
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% Adhesion Strength vs. Curing Time 
(cow bone, no UV light)
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70 80 90 10
0
11
0
12
0
Curing Time (sec)
Ad
he
s
io
n
 
St
re
n
gt
h 
(%
)
Trial 1
Trial 2
 
Figure B.1   Adhesion strength vs. curing time (cow bone, no UV light) 
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Figure B.2  Adhesion strength vs. curing time (NY steak, no UV light) 
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% Adhesion Strength vs. Curing Time 
(cow bone, UV light)
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Figure B.3  Adhesion strength vs. curing time (cow bone, UV light) 
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Figure B.4  Adhesion strength vs. curing time (NY steak, UV light) 
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Several conclusions were made from the above experiment: 
• Saliva does not affect the ability of the implant to adhere to bone.  Thus, blood,  
with chemical and physical components somewhat similar to blood, is also     
assumed to have little effect on the ability of the implant to adhere to bone.    
• The curing time with UV light is less than the curing time without UV light.  
      However, the difference is not that significant. 
 
B.2   Using the INFUSE® Bone Graft Sample Kit  
Note: A buffer was used to substitute for the rhBMP-2 in the sample kit 
Questions to be answered from the experiment: 
• Is it possible or necessary to separate the rhBMP-2 and sterile water into separate 
vials for smaller samples? If so, how should this be done? 
• Is the effectiveness of the rhBMP-2 / sterile water mixture compromised if it is 
not used all at one time? 
• What tools are necessary to cut the absorbable collagen sponge (ACS) into its 
desired shape?  
• Should the collagen sponge be cut before or after the rhBMP-2 / sterile water 
mixture is applied to it? 
• How much ACS is need for one implant?  
• 4.0 mL of the rhBMP-2 / sterile water mixture is needed for 3 collagen sponges. 
How much of the reconstituted rhBMP-2 is needed for just 1 collagen sponge? ½ 
of a collagen sponge? Etc.? 
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• How can a hole be created in the middle of the shaped sponge for the protruding 
part of the implant when the rhBMP-2/ACS is placed on top of the TAD? (Note: 
this is not applicable for this particular study, which solely focuses on the effect 
of rhBMP-2/ACS placed underneath the implant). 
• Since the kit states that the wet collagen sponges must be used within 2 hours, 
how many rats can undergo surgery within 2 hours with the assumption that the 
sponges will be prepared before the surgeries begin?  
 
Experimental procedure 
• Take a 10 mL syringe out into the field, and draw 8.4 mL of sterile water into the 
syringe. 
• Inject 8.4 mL of sterile water into the buffer powder vial and swirl the vial to 
ensure adequate mixing. 
• Open the collagen sponge package and take out one of the collagen sponges. 
• Since 4 mL of the rhBMP-2 / sterile water mixture is needed for 3 collagen 
sponges, calculate the amount of mixture needed for 1 collagen sponge: 4 mL / 3 
sponges = 1.33 mL / sponge. 
• Use another 10 mL syringe to withdraw 1.33 mL of reconstituted rhBMP-2 from 
the vial. 
• Uniformly distribute 1.33 mL of reconstituted rhBMP-2 on 1 of the 2.5 cm x 5 cm 
collagen sponges.  
• Allow the wet collagen sponge to stand for 15 minutes. 
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• After 15 minutes, use 2 different tools to cut the collagen sponge in the shape of 
the implant. 
• Place a sample implant on the collagen sponge and used an x-acto knife to cut 
around the outer edge of the implant. 
• Using another section of the collagen sponge, use a 1-hole punch to punch a hole 
through the wet sponge. 
• Take out a second collagen sponge. This time, cut the non-wetted sponge with the 
x-acto knife. Likewise, use the 1-hole punch on the non-wetted sponge. 
 
Experimental Results and Conclusions 
• It is not necessary to separate the rhBMP-2 and sterile water into smaller vials.  
As long as the reconstituted rhBMP-2 is refrigerated, it can be used at another 
point in time.  The effectiveness of the rhBMP-2 / sterile water mixture is not 
compromised if it is not used all at once. The kit instructions state that the wet 
collagen sponge must be used within 2 hours, but there is nothing stating that the 
rhBMP-2 / sterile water mixture must be used within 2 hours.  
• The 1-hole punch is not a good tool for the purposes of this study because it 
punches out a diameter that is smaller than the diameter of the implant for both 
the non-wetted and wet sponge.  
• It is difficult to cut a circular shape with the x-acto knife on a wet sponge. 
However, the x-acto knife works better when making straight cuts on the wet 
sponge.  
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• It is difficult to cut a circular shape through a non-wetted sponge with the x-acto 
knife, but easy to cut straight lines.  
• Cutting the non-wetted sponge is easier than cutting the wet sponge. 
• A 1.00 cm x 1.25 cm section (1/10 of 1 collagen sponge) of a non-wetted sponge 
is needed for 1 implant. Once the sponge is wet, it can be shaped circularly to 
follow the shape of the implant.  
• Use the following procedure to prepare the rhBMP-2/ACS for the implant: 
1. Cut one non-wetted collagen sponge (2.5 cm x 5 cm) into 10 equal 
sections (1.00 cm x 1.25 cm). 
 
Figure B.5   Absorbable collagen sponge (figure not drawn to scale) 
 
2. Apply the rhBMP-2 / sterile water mixture to a 1.00 cm x 1.25 cm section 
of ACS. Since 4 mL of the rhBMP-2 / sterile water mixture is needed for 3 
collagen sponges, the amount of mixture needed for 1 collagen sponge is 4 
mL / 3 sponges = 1.33 mL / sponge.  However, since one collagen sponge 
is divided into 10 equal sections, 1/10 * 4/3 = 0.133 mL of the rhBMP-2 / 
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sterile water mixture is needed per section.  The syringe given in the kit is 
a 10 mL syringe with increments of 0.2 mL.  For better accuracy, use a 
smaller syringe with smaller increments. 
3. After waiting at least 15 minutes, place the wet collagen sponge on the rat 
skull location where the implant will be placed, contouring the shape to fit 
the circular shape of the implant.  Set the implant over the wet collagen 
sponge. 
• Since the wet collagen sponge must be used within 2 hours, only wet a 1.00 cm x 
1.25 cm section of absorbable collagen sponge before each rat goes through 
surgery. 
• Note: the collagen sponge pieces used during the actual surgery were different in 
size than those used during the experimental phase.  Specifically, 1 cm x 1 cm 
pieces were used with 0.09 cc of reconstituted rhBMP-2. 
 
B.3   Using One Rat to Determine the Following 
1. Effectiveness of the type of anesthesia 
A mixture of Ketamine and Xylazine (44 mg/kg body weight of Ketamine, 
10 mg/kg body weight of Xylazine) should be used for inducing general 
anesthesia. The source used to determine these dosages is Lumb and Jones 
Veterinary Anesthesia and Analgesia, 4th Ed. by W. J. Tranquilla.  In addition, a 
dose of Buprenorphine should be administered subcutaneously (0.01-0.05 mg/kg) 
between the shoulder blades to mitigate pain [24].  The Ketamine/Xylazine 
mixture provides approximately 30 minutes of effective anesthesia, and a ½ dose 
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must be available to continue the anesthesia if the surgery takes longer than 
expected.  The Ketamine/Xylazine and Buprenorphine mixture works well 
because emergence from anesthesia is smoother and it has a high factor of safety. 
The reason why the Ketamine/Xylazine and Buprenorphine mixture is chosen 
over an inhalant anesthetic, such as Halothane, is because Halothane requires that 
the rats wear a mask during surgery. Unfortunately, this mask would interfere 
with the surgical site, and therefore the Ketamine/Xylazine and Buprenorphine 
mixture is the better choice.   
 
2. Instrumentation needed 
Tray for BMP-2 procedures, BMP-2 / ACS, syringes, forceps, fine 
forceps, ultrafine forceps, weight boat, bench covers, sterile gowns, scrubs, mask, 
rat gloves, nitrile gloves, sterile gloves, Ketamine, Xylazine, Buprenorphine, 
shaver, depilatory cream (Veet®), Betadine solution, Petri dish with saline, 
surgical drapes, scissors, scalpel, butyl cyanoacrylate / applicator, glass slab for 
butyl, head cap, cotton gauze and swabs (both sterile and non-sterile), disposable 
bag for blood and contaminated items, heating pad, recovery bin, etc. 
 
3. Preparation / surgical procedures 
 A clean, uncluttered, and sanitized work surface should be used for prep 
and surgery.  Aseptic procedures must be followed:   
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            Pre-operative:   
a. Sterilize instruments (using the method of heat sterilization) needed for 
prep and surgery: tray for rhBMP-2 procedures, forceps, fine forceps, 
ultrafine forceps, scissors, scalpel, butyl cyanoacrylate applicator, glass 
slab for butyl, surgical drapes, syringes, gloves, Petri dish with saline, 
cotton gauze, and cotton swabs. 
b. Bring to surgical suite: sterile instruments mentioned above as well as 
butyl cyanoacrylate, tupperware for weighing the rat, isolation mask and 
cap, sterile gowns, bench covers, weight boat, and rat in the cage. 
c. Obtain in surgical suite: Ketamine, Xylazine, Buprenorphine, scrubs, rat 
gloves, nitrile gloves, sterile gloves, shaver, depilatory cream (Veet®), 
Betadine solution, disposable bag for blood and contaminated items, 
heating pad, recovery bin, and non-sterile cotton swabs and gauze. 
d. In an area of the surgical suite, separate from the prep and surgery area, an 
assistant must wash their hands, put on sterile gloves, and do the 
following:  
• For a control TAD, take a 1 cm x 1 cm absorbable collagen 
sponge with sterile forceps and wet it with 0.09 cc of saline 
using a sterile syringe and a sterile tray.  Let it stand for at least 
15 minutes before use. 
• For an rhBMP-2 treated TAD, take a 1 cm x 1 cm absorbable 
collagen sponge with sterile forceps and wet it with 0.09 cc of 
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reconstituted rhBMP-2 using a sterile syringe and a sterile tray.  
Let it stand for at least 15 minutes before use.  
• Meanwhile, continue with the following pre-operative 
procedures. 
e. Weigh the animal in a weight boat to determine the appropriate dosages of 
Ketamine, Xylazine, and Buprenorphine.  The amount of anesthesia given 
to a rat is determined by the following criteria: 44 mg/kg body weight of 
Ketamine, 10 mg/kg body weight of Xylazine, and 0.01 – 0.05 mg/kg 
body weight of Buprenorphine.  Record the dosages in the lab notebook.  
f. Place a bench cover down on the table. 
g. Put on rat gloves and grab the animal around the torso to administer the 
anesthesia.  Use a mixture of Ketamine and Xylazine (44 mg/kg body 
weight of Ketamine, 10 mg/kg body weight of Xylazine) for inducing 
general anesthesia.  This will provide approximately 30 minutes of 
effective anesthesia. 
h. In addition, administer a dose of Buprenorphine subcutaneously (0.01 – 
0.05 mg/kg body weight) between the shoulder blades.  The 
Ketamine/Xylazine and Buprenorphine mixture works well because 
emergence from anesthesia is smoother and has a high factor of safety.  
Place the rat in a chamber until the anesthesia takes effect and the animal 
is down. 
i. Throw out the bench cover and place a new one for prepping.  An assistant 
will start the prepping of the animal while the individual performing the 
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surgery starts the surgical scrub and puts on a sterile gown to prepare for 
surgery. 
j. Assistant: put scrubs and nitrile gloves on for prepping procedures. 
k. Take the rat out of the chamber and place on the bench cover.  Use the 
clippers provided in the surgical suite to shave the surgical site (rat’s 
head).  Then, apply depilatory cream on the surgical site.  Wait a few 
minutes for the depilatory cream to set. Rub the surgical site with a damp 
2 x 2 cotton sponge to remove excess hair.     
l. Pour Betadine antiseptic solution on a swab and apply it to the rat’s head 
in a circular motion.  Repeat a minimum of 3 times.  Put the animal back 
in the chamber. 
m. Throw away the bench cover.  
n. Disinfect the table to maintain a clean, uncluttered, and sanitized area.  
Use gauze sponge to wipe it down. 
o. Place down a new bench cover. 
p. Put the rat down on the new bench cover. 
q. Take off nitrile gloves and wash hands. 
r. Take pre-sterile surgical packages with surgical drape and sterile 
instruments, sterile gloves, isolation mask and cap, butyl 
cyanoacrylate/applicator, glass slab, gauze, and cotton swabs and place 
them on the table within reach of the individual performing surgery. 
s. Put the heating pad in the microwave so it is ready to heat up once surgical 
procedures are completed. 
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t. Open up the sterile surgical package cover, and open up covering for 
sterile instruments (without touching the actual instruments). 
u. Once the “surgeon” has scrubbed and put on the sterile gown, he/she must 
put on the sterile gloves and sit down to begin surgery. 
v. The surgeon should now pull out the surgical drape from the sterile 
surgical packages and place it on the animal.  Use forceps and scissors to 
cut drape at incision site. Use other forceps and scissors to do actual 
incision (internal work). 
 
Operative: 
a. Begin surgery with sterile instruments and handle instruments aseptically. 
b. Using the “tips-only” technique, make an incision along the line from the 
middle of the eyes to the middle of the ears.   
c. Once the incision is made, carefully fold back the periosteum using sterile 
instruments (i.e. scalpel, forceps, etc.). 
d. When the bony complex on the surface of the cranium is exposed, use 
sterile forceps to pick up a titanium implant and contour it to fit the skull 
shape.  Use a sterile instrument to place the collagen sponge (wet with 
saline or rhBMP-2) on the rat skull before placing the implant on top of it 
and stabilizing it with butyl cyanoacrylate.  Wait approximately 2 minutes 
for the butyl cyanoacrylate to set.  
e. While surgery is in progress, continually monitor the animal’s vital signs.   
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f. Once the implant is stable, place as much of the periosteum over the 
implant.   
g. Use sterile forceps to hold the sides of skin at the incision site together 
while an assistant closes the incision site using butyl cyanoacrylate.  At 
this point, have another assistant go to the microwave to heat up the 
circulating heating pad for about 3-4 minutes to heat up to 37 degrees. 
 
Post-Operative: 
a. Remove the surgical drape. 
b. Give the rat a subcutaneous injection of Buprenorphine (0.01 - 0.05 
mg/kg). 
c. Move the rat to a warm area (recovery bin) to return its body temperature 
back to normal.  In the recovery bin, place the rat on a blue bench cover, 
above a heating pad, to allow it to recover.  Return the animal to its 
routine housing only after full recovery from anesthesia.  Each rat will be 
caged separately. 
d. Buprenorphine (0.01 -0.05 mg/kg) should be administered 3 times a day 
for 2 days as necessary for pain management.  In the event of an infection, 
the wound site will be cleaned 2 times/day with Betadine solution. 
e. The rats will be visually inspected daily post-op for infection.  A surgical 
record (procedure, date, anesthesia dose, route of administration) will be 
maintained. 
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4. Surgical site to least elicit blood flow, angulations, and location of incision 
The incision should be made in such a way that it elicits the least amount 
of blood flow. In terms of the vascular structures in a rat, the common carotid 
artery splits into the internal and external carotid arteries ventral to the auditory 
bulla (bony capsule enclosing the middle and inner ear). The internal carotid 
artery moves anteriorly to supply blood to the brain and the external carotid artery 
moves anteriorly to supply blood to most of the structures of the head.  To avoid 
compromising the rat’s vascular system, an incision approximately 1 inch in 
length should be made along the midline of the skull. The midline incision in the 
scalp should be made using firm pressure to guarantee a clean cut in a single 
stroke. The incision should be made from the area between the eyes to the area 
between the ears. Then, once the incision is made, the periosteum can be carefully 
removed. The periosteum can be pulled back and removed from the skull using 
scalpel, forceps and scissors. 
 
5. Implant contour, adhesion method, and incision site closure  
The sites should be chosen such that the TAD follows the contour of the 
skull in the best way possible. The TAD should be placed on the cranial bone 
such that its distance from the cranial surface is as close as possible.  Only one 
implant can be successfully placed on the skull and covered with the periosteum. 
The periosteum is too thin and does not sufficiently cover two implants at one 
time.  Therefore, only one implant will be used for each rat.  Butyl cyanoacrylate 
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will be used to ensure the adhesion of the implant to the bone and for closure of 
the incision. 
 
6. Implant size and protruding length 
One 7 mm diameter TAD can fit on one rat skull.  A protruding length of 
2 mm on one side is sufficient enough for biomechanical testing and small enough 
to prevent the rat from knocking it off.  The surgical procedures should be purely 
subcutaneous so that the protruding part of the implant will be under the skin. 
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Appendix C 
Surgery Checklist 
Date____________                        Rat Skull Surgery                      Initials____________  
 
Rat Information 
Breed: _______________ 
Sex:  ________________ 
Weight: ______________ 
Tag: _________________ 
Cage: ________________ 
 
Materials 
Sterilized Instruments 
___1.   forceps 
___2.   fine forceps 
___3.   ultrafine forceps 
___4.   scissors 
___5.   scalpel 
___6.   cotton gauze 
___7.   cotton swabs 
 
Bring to Surgical Suite 
___8.   sterile surgical drapes 
___9.   sterile syringes 
___10.   butyl cyanoacrylate/applicator/glass slab 
___11.   sterile gown, mask and cap 
___12.   bench covers 
___13.   weight boat 
 
Obtained in Surgical Suite 
___14.   anesthesia (Ketamine and Xylazine) 
___15.   analgesic (Buprenorphine) 
___16.   scrubs 
___17.   rat gloves 
___18.   sterile gloves 
___19.   shaver 
___20.   depilatory cream (Veet®) 
___21.   Betadine solution 
___22.   disposable bag for blood and contaminated items 
___23.   heating pad 
___24.   recovery bin 
___25.   non-sterile cotton swabs  
___26.   non-sterile cotton gauze 
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rhBMP-2/ACS or Saline/ACS Preparation 
___27.   Take a 1 cm x 1 cm absorbable collagen sponge and wet it with 0.09 cc of  
   reconstituted rhBMP-2 or saline (if control TAD). 
___28.   Let collagen sponge stand for at least 15 minutes before use. 
 
Surgery Preparation 
___29.   Weigh animal in weight boat. 
___30.   Put on rat gloves and grab animal around torso to administer anesthesia. Use a  
   mixture of Ketamine and Xylazine (44 mg/kg body weight of Ketamine, 10  
   mg/kg body weight of Xylazine).  Record dosages in the lab notebook.  
___31.   Give the rat a subcutaneous injection of Buprenorphine (0.01 – 0.05 mg/kg  
   body weight). Record dosage in the lab notebook.  
___32.   Place rat in chamber (anesthesia box) to let the anesthesia take effect. 
___33.   Surgeon: put on mask/cap, perform surgical scrub, and put on sterile gown and    
              gloves to prepare for surgery. 
___34.   Assistant: put scrubs and nitrile gloves on.  Perform prepping procedures below. 
___35.   Place bench cover on table for preparation procedures. 
___36.   Take rat out of chamber and place on bench cover. 
___37.   Shave hair on surgical site (rat’s head) using clippers. 
___38.   Apply depilatory cream to surgical site and wait a few minutes. 
___39.   Rub surgical site with a damp 2 x 2 cotton sponge to remove excess hair. 
___40.   Apply Betadine solution on the rat’s head a minimum of 3 times in a circular  
              motion. 
___41.   Return rat to chamber.  
___42.   Throw away bench cover. 
___43.   Disinfect table. Use gauze to wipe it down.                           
___44.   Place down a new bench cover. 
___45.   Put the rat down on the new bench cover. 
___46.   Take off nitrile gloves and wash hands. 
___47.   Place pre-sterile surgical packages (with sterile drape), sterile instruments, sterile  
   gloves, and isolation mask and cap on the table. 
___48.   Place heating pad in microwave so it is ready to heat up once surgery is done. 
___49.   Put on mask and cap. 
___50.   Open up sterile surgical packages (sterile drape and instruments) without    
              touching the inside of the sterile packages. 
 
Surgery 
___51.   Surgeon: pull out sterile surgical drape from sterile package and put over rat.     
              Perform surgery procedures below. 
___52.   Use forceps and scissors to cut drape at incision site. 
___53.   Make an incision along the midline of the rat’s head, from the middle of the eyes  
   to the middle of the ears. 
___54.   Carefully fold back the periosteum using forceps. 
___55.   Use sterile forceps to pick up a titanium implant and contour it to fit the shape of  
   the skull. 
___56.   Use a sterile instrument to place the collagen sponge (wet with saline or rhBMP- 
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              2) on the rat skull before placing the TAD on top of it. 
___57.   Stabilize the TAD with butyl cyanoacrylate and let it set for approximately 2    
              minutes.     
___58.   Close the incision using butyl cyanoacrylate.  At this time, have an assistant                   
              microwave the heating pad for about 45 seconds. 
 
Post-Surgical 
___59.   Remove surgical drape. 
___60.   Give the rat a subcutaneous injection of Buprenorphine (0.01 – 0.05 mg/kg). 
___61.   Place rat in recovery bin, on a blue bench cover, above a heating pad to allow to 
   recover. 
___62.   Return rat to its routine housing only after full recovery from anesthesia. Each  
   rat will be caged separately. 
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Appendix D 
Anesthetics/Analgesics 
D.1  Bottle Concentrations (mg/mL) 
Ketamine HCl: 100 mg/mL 
Xylazine: 20 mg/mL 
Buprenorphine HCl: 0.3 mg/mL 
 
D.2   Dosage (mg/kg of body weight) 
Ketamine HCl: 44 mg/kg 
Xylazine: 10 mg/kg 
Buprenorphine HCl: 0.03 mg/kg 
 
Table D.1   Number of mL administered of each drug based on weight 
Weight of Rat (g) Weight of Rat (kg) Ketamine (mL) Xylazine (mL) Buprenorphine (mL) 
200 0.200 0.088 0.100 0.020 
205 0.205 0.090 0.103 0.021 
210 0.210 0.092 0.105 0.021 
215 0.215 0.095 0.108 0.022 
220 0.220 0.097 0.110 0.022 
225 0.225 0.099 0.113 0.023 
230 0.230 0.101 0.115 0.023 
235 0.235 0.103 0.118 0.024 
240 0.240 0.106 0.120 0.024 
245 0.245 0.108 0.123 0.025 
250 0.250 0.110 0.125 0.025 
255 0.255 0.112 0.128 0.026 
260 0.260 0.114 0.130 0.026 
265 0.265 0.117 0.133 0.027 
270 0.270 0.119 0.135 0.027 
275 0.275 0.121 0.138 0.028 
280 0.280 0.123 0.140 0.028 
285 0.285 0.125 0.143 0.029 
290 0.290 0.128 0.145 0.029 
295 0.295 0.130 0.148 0.030 
300 0.300 0.132 0.150 0.030 
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305 0.305 0.134 0.153 0.031 
310 0.310 0.136 0.155 0.031 
315 0.315 0.139 0.158 0.032 
320 0.320 0.141 0.160 0.032 
325 0.325 0.143 0.163 0.033 
330 0.330 0.145 0.165 0.033 
335 0.335 0.147 0.168 0.034 
340 0.340 0.150 0.170 0.034 
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Appendix E 
 
Photographs of TAD Bone Coverage   
 
Table E.1   Visual inspection: TAD bone coverage 
Rat # Control or rhBMP-2 treated Bone Coverage 
Rat 4 Control, sponge on bottom 
Bone coverage observed; however, data 
discarded as TAD was left in rat for over 6 
weeks 
Rat 8 Control, sponge on bottom 
 
Rat 12 Sponge on bottom w/ rhBMP-2 
 
Rat 13 Control, sponge on bottom 
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Rat 14 Sponge on bottom w/ rhBMP-2 
 
Rat 15 Sponge on bottom w/ rhBMP-2 
 
Rat 16 Control, sponge on bottom 
 
Rat 17 Sponge on bottom w/ rhBMP-2 
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Rat 18 Sponge on bottom w/ rhBMP-2 
 
Rat 20 Control, sponge on bottom No bone coverage observed – TAD stuck to 
soft tissue 
Rat 25 Sponge on bottom w/ rhBMP-2 
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Appendix F 
 
Failure Load Graphs from Biomechanical Testing    
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Figure F.1   Force-displacement curve for Rat 8 
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Figure F.2   Force-displacement curve for Rat 12 
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Figure F.3   Force-displacement curve for Rat 13 
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Figure F.4   Force-displacement curve for Rat 14 
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Rat 15
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Figure F.5   Force-displacement curve for Rat 15 
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Figure F.6   Force-displacement curve for Rat 16 
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Figure F.7   Force-displacement curve for Rat 17 
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Figure F.8   Force-displacement curve for Rat 18 
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Figure F.9   Force-displacement curve for Rat 25 
  
 
